Viatris: Complex Injectable Pipeline Opportunities Worth At Least $1bn

Raft Of Complex And Novel Assets Targeted Under ‘Phase Two’ Roadmap

 
• By Dean Rudge

A generic version of Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) treatment for obesity is among seven complex generic injectables for which Viatris is claiming first-to-file status, as it looks to return to growth in 2024 and beyond.

hands holding jigsaw puzzles, business to business, business matching concept
Viatris has pieced together a pipeline of FTF injectables • Source: Shutterstock

More from Strategy

More from Business